Inhaled Treprostinil for PAH: Open-label Extension

Phase 3WithdrawnNCT01557660

United Therapeutics

Overview

Open-label extension of RIN-PH-302.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

0.6mg/mL inhalation solution, up to 12 breaths four times a day

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Participation and completion of all required visits for study RIN-PH-302.

Long term safety of inhaled treprostinil

Time frame: up to 5 years

Six-minute walk distance

Time frame: up to 5 years

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.